Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults
Open Access
- 3 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 59 (2) , 140-149
Abstract
Objectives: Gadolinium (Gd)–based contrast agents are well established in clinical routine and have been proven safe and effective. However, there is a need for “next-generation” Gd-based contrast agents that would allow lowering the Gd dose used for routine contrast-enhanced magnetic resonance imaging procedures. The objective of this first-in-human study was to investigate the pharmacokinetic profile, safety, and tolerability of gadoquatrane, a novel high-relaxivity Gd-based contrast agent. Materials and Methods: This study was conducted in 2018/2019 as a prospective, randomized, single-blind, single-dose, placebo-controlled, escalating-dose study. Healthy volunteers were randomly assigned (6:2) to intravenous administration of gadoquatrane (0.025 to 0.2 mmol Gd/kg body weight) or placebo. Study procedures included collection of blood samples and excreta for pharmacokinetic analyses and safety assessments. Results: Forty-nine healthy study participants (mean age ± SD, 35 ± 6.3 years; 24 female) were evaluated. The effective half-life of gadoquatrane in plasma was short and similar in all dose groups (1.4–1.7 hours). Plasma concentrations around the lower quantitation limit (0.0318 μmol Gd/L) were reached 15–72 hours after administration. The volume of distribution at steady state was ~0.2 L/kg in all dose groups. The clearance (total and renal) was ~0.1 L/h per kilogram in all groups. Across dose groups, the exposure of gadoquatrane increased dose-proportionally. Metabolite profiling revealed no hint of degradation in vivo or release of free Gd. Seven of 36 participants (19.4%) receiving gadoquatrane and 4 of 13 participants (30.8%) receiving placebo experienced mild or moderate treatment-emergent adverse events. No serious adverse events occurred. The analysis of the Gd concentration-QTc interval relationship indicated no risk of QT/QTc prolongation (>10 milliseconds) with gadoquatrane at clinical dose levels. Conclusions: Gadoquatrane with its high-relaxivity, pharmacokinetic similarity to established Gd-based contrast agents and high tolerability is a promising “next-generation” contrast agent for magnetic resonance imaging.Keywords
This publication has 17 references indexed in Scilit:
- Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium ChelatesRadiology, 2018
- Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic ResonanceInvestigative Radiology, 2018
- Correction to: Scientific white paper on concentration-QTc modelingJournal of Pharmacokinetics and Pharmacodynamics, 2018
- Scientific white paper on concentration-QTc modelingJournal of Pharmacokinetics and Pharmacodynamics, 2017
- Gadolinium deposition in the brain: summary of evidence and recommendationsThe Lancet Neurology, 2017
- High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast MaterialRadiology, 2014
- Biodistribution of gadolinium‐based contrast agents, including gadolinium depositionJournal of Magnetic Resonance Imaging, 2009
- Mechanism-Based Concepts of Size and Maturity in PharmacokineticsAnnual Review of Pharmacology and Toxicology, 2008
- Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrology Dialysis Transplantation, 2006
- Pharmacokinetics, Dose Proportionality, and Tolerability of Gadobutrol after Single Intravenous Injection in Healthy VolunteersInvestigative Radiology, 1994